PI16

Across TCGA pan-cancer cohorts, PI16 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PI16 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PI16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PI16 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where PI16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.565	0.916	.006	24	view →
CCRCC	DFS	Tertile	All	0.912	0.519	.002	19	view →
UCEC	OS	Quartile	II,III,IV	0.281	1.000	.018	8	view →
LSCC	OS	Tertile	III,IV	0.856	0.568	.043	4	view →
HNSC	DFS	Quartile	III,IV	1.000	0.891	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PI16–LUAD (DFS)

Open the LUAD breakdown →